SPOTLIGHT: Mining companies fund trial
A group of mining companies has agreed to provide $6 million to Australia's Virax to funds tests of its HIV therapy, VIR201. The innovative funding program was inspired by the companies' problems wrestling with the AIDS epidemic that afflicts miners in South Africa. Report
Be the first to comment
Comments
Post new comment
Paid Research Reports
- RNA therapy: the next big thing after monoclonal antibodies?
- Biotech M&A Strategies: Deal assessments, trends and future prospects
- The Dermatology Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities
- Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor t
- Sales Force Effectiveness
- Forecast Model: Antidyslipidemics - Genericization and negative trial data drive market shrinkage
